Skip to main content
Journal cover image

Telaprevir for the treatment of chronic hepatitis C infection.

Publication ,  Journal Article
Muir, AJ
Published in: Expert Rev Anti Infect Ther
December 2011

Telaprevir is an NS3/4A protease inhibitor that has recently received US FDA approval for the treatment of chronic HCV infection. Telaprevir is given in combination with peg-IFN-α and ribavirin and is indicated for both treatment-naive and treatment-experienced patients with genotype 1 infection. Along with the other first generation NS3/4A protease inhibitor boceprevir, these combination regimens have immediately become the standard of care for genotype 1 patients. The adverse event profile for the combination regimen remains dominated by peg-IFN-α and ribavirin, but there is additional anemia and rash with telaprevir. Owing to telaprevir's metabolism by the CYP3/4A pathway, drug-drug interactions could lead to toxicity from other medications or decreased efficacy of telaprevir. Viral resistance can develop during treatment with telaprevir, and patients will need to be educated on their role in adherence to minimize the risk of resistance and improve their chances of cure of HCV infection.

Duke Scholars

Published In

Expert Rev Anti Infect Ther

DOI

EISSN

1744-8336

Publication Date

December 2011

Volume

9

Issue

12

Start / End Page

1105 / 1114

Location

England

Related Subject Headings

  • Viral Nonstructural Proteins
  • Ribavirin
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Protease Inhibitors
  • Proline
  • Polyethylene Glycols
  • Oligopeptides
  • Mutation
  • Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Muir, A. J. (2011). Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther, 9(12), 1105–1114. https://doi.org/10.1586/eri.11.133
Muir, Andrew J. “Telaprevir for the treatment of chronic hepatitis C infection.Expert Rev Anti Infect Ther 9, no. 12 (December 2011): 1105–14. https://doi.org/10.1586/eri.11.133.
Muir AJ. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105–14.
Muir, Andrew J. “Telaprevir for the treatment of chronic hepatitis C infection.Expert Rev Anti Infect Ther, vol. 9, no. 12, Dec. 2011, pp. 1105–14. Pubmed, doi:10.1586/eri.11.133.
Muir AJ. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105–1114.
Journal cover image

Published In

Expert Rev Anti Infect Ther

DOI

EISSN

1744-8336

Publication Date

December 2011

Volume

9

Issue

12

Start / End Page

1105 / 1114

Location

England

Related Subject Headings

  • Viral Nonstructural Proteins
  • Ribavirin
  • Recombinant Proteins
  • Randomized Controlled Trials as Topic
  • Protease Inhibitors
  • Proline
  • Polyethylene Glycols
  • Oligopeptides
  • Mutation
  • Microbiology